Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine
- 作者：Francesca Buchi ; Elena Spinelli ; Erico Masala ; Antonella Gozzini ; Alessandro Sanna ; Alberto Bosi ; Germano Ferrari ; Valeria Santini ; santini@unifi.it
- 关键词：AML ; Proteomics ; Azacitidine ; Decitabine
- 刊名：Leukemia Research
- 出版年：2012
- 期刊代码：186_01452126
- 类别：med
- 出版时间：May, 2012
- 卷：36
- 期：5
- 页码：607-618
- 文件大小：2514 K
摘要
Azacitidine and decitabine are DNA methyltransferase inhibitors used to treat myelodysplastic syndromes and acute myeloid leukemias. To further characterize different mechanisms between these two agents, cellular extracts from leukemic cells untreated or treated with either drug were analyzed using 2D electrophoresis. Numerous differentially expressed proteins were identified with MALDI-TOF/TOF-MS. Cyclophilin A, Catalase, Nucleophosmin and PCNA were decreased exclusively by azacitidine, TCP1 and hnRNP A2/B1 by both drugs; alpha-Enolase and Peroxiredoxin-1 by decitabine. Interestingly, the expression of the proinflammatory protein Cyclophilin A, also suggested as marker of cell necrosis, was stimulated by decitabine. Finally, a comprehensive pathway analysis of data highlighted a relationship between the identified proteins and potential effectors.